In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.&n...
All content for Clinical Capsules is the property of TRC Healthcare and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.&n...
Zepbound for Zzz’s: Exploring Tirzepatide for Sleep Apnea
Clinical Capsules
14 minutes
3 months ago
Zepbound for Zzz’s: Exploring Tirzepatide for Sleep Apnea
In this episode, TRC Healthcare editor, Sara Klockars, PharmD, BCPS unpacks the newly approved use of tirzepatide (Zepbound) for obstructive sleep apnea (OSA)—a first-in-class pharmacologic option for a condition long managed with devices and lifestyle changes. You’ll hear a concise review of sleep apnea pathophysiology, how tirzepatide works to reduce airway obstruction, and what the latest clinical trials reveal about its efficacy and safety. Plus, you’ll get practical pharmacy-focuse...
Clinical Capsules
In this episode, Rachel Cole, PharmD, explores the evolving landscape of medications for HIV pre-exposure prophylaxis (PrEP), spotlighting lenacapavir (Yeztugo)—a newly approved long-acting injectable option given just twice yearly. She walks through how it compares to oral therapies like Truvada and Descovy, plus other injectables such as cabotegravir. Rachel also offers practical guidance on identifying candidates for HIV PrEP, navigating lab requirements, and managing side effects.&n...
